Company Product Description Indication Status
Decipher Biosciences Inc., of San Diego Decipher Prostate RP Genomic test For guiding post-operative management decisions in patients with prostate cancer Study published in Prostate Cancer and Prostatic Diseases demonstrates the clinical utility of the Decipher Prostate Genomic Classifier after radical prostatectomy; reported a 3% rate of disease progression in Decipher low- and intermediate-risk patients who followed treatment recommendations; Decipher high-risk patients who did not follow recommendation of immediate treatment experienced a 25% rate of disease progression, whereas only 3% of those who followed the recommendation progressed
Rivanna Medical, of Charlottesville, Va. Accuro Automated spinal navigation system Improves the safety, speed, and efficiency of epidural and spinal anesthesia In a trial, published in the Regional Anesthesia & Pain Medicine Journal, researchers compared the accuracy of spinal anesthesia placement using the Accuro vs. a traditional palpation-based approach in obese patients undergoing orthopedic surgery; found that patients given a spinal block under Accuro ultrasound-based spinal navigation experienced a median number of 3 needle redirects (from 0 to 9) and 1 needle pass through the skin (from 1 to 2) compared to 6 (from 1 to 16) and 1 (between 1 and 2) respectively for conventional spinal palpation for bony landmarks; both endpoints were statistically significant in this study enrolling 130 patients
Sysmex Inostics GmbH, of Hamburg, Germany SafeSEQ Liquid biopsy test Detects ctDNA variants for treatment response and recurrence in early-stage breast cancer Demonstrated a potential utility for monitoring tumor-specific mutations (TSMs) in the circulation of early-stage, triple-negative breast cancer patients; in 228 patients with stage II and III triple-negative or HER2-positive breast cancer, TSMs were identified in 48% (37/77) of the pre-therapy samples, of which 89% had detectable plasma TP53 mutations, 11% had PIK3CA mutations, and 11% had co-occurring TP53 and PIK3CA mutations


For more information about individual companies and/or products, see Cortellis.

No Comments